Haleon plc (LSE/NYSE:HLN), a global leader in consumer health with a market capitalization of $44 billion, disclosed a transaction by a person discharging managerial responsibilities (PDMR) today. According to InvestingPro data, the company has demonstrated strong performance with a 20% year-to-date return.
General Counsel Adrian Morris was granted a 3-year option over ordinary shares under the company's 2024 Share Save Plan. The option, priced at £3.00 per share, involves 6,150 shares and will first become exercisable on February 1, 2028. This transaction took place outside a trading venue on Thursday, December 19, 2024.
The notification, made in accordance with the UK Market Abuse Regulation, marks an initial disclosure for Morris. The option grant is part of Haleon's strategy to incentivize its executives, aligning their interests with the company's long-term performance. InvestingPro analysis shows the company maintains impressive gross profit margins of 62.2% and generally trades with low price volatility, with additional insights available through the Pro Research Report.
Haleon, known for brands such as Advil, Sensodyne, and Centrum, operates in various health categories including Oral Health, Pain Relief, and Vitamins, Minerals, and Supplements. The company's commitment to delivering better everyday health is underpinned by trusted science and innovation, reflected in its GOOD financial health score according to InvestingPro metrics.
In other recent news, Haleon plc, a leading consumer healthcare company, has made significant strides in its financial and strategic operations. The company reported impressive earnings and revenue results, including the completion of a £230 million off-market share repurchase from Pfizer Inc. (NYSE:PFE) Haleon also increased its stake in the Chinese joint venture, Tianjin TSKF Pharmaceutical (TADAWUL:2070) Co. Ltd, to 88%, and finalized the divestment of its nicotine replacement therapy business to Dr. Reddy's Laboratories SA, in a deal worth up to £500 million.
Haleon announced key changes to its board, with David Denton resigning as a Non-Executive Director following a decrease in Pfizer's shareholding, and Bláthnaid Bergin stepping in as an independent Non-Executive Director. The company's CFO, Dawn Allen, vested an award of Haleon Ordinary Shares and sold a portion to cover tax obligations, retaining a significant number of shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.